Plain-English translation of NCT05058846 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a screening study for people who carry specific genetic mutations (BRCA1, BRCA2, ATM, or PALB2) that put them at higher risk for pancreatic cancer. Researchers want to see if regular MRI and ultrasound imaging can detect early warning signs or precancerous changes before they become dangerous. The study will follow participants for up to 10 years.
Pancreatic cancer is hard to catch early because it often has no symptoms in its early stages. People with certain genetic mutations have a much higher risk of developing this disease. This trial aims to find out whether regular screening imaging can catch problems earlier, when treatment might be more effective.
You likely qualify if…
You likely don't qualify if…
Depending on your family history and which group you're in, you'll receive annual MRI and/or ultrasound imaging scans of your pancreas for up to 10 years. You'll also be asked to complete surveys about your knowledge and feelings regarding pancreatic cancer screening. Some participants may also choose to donate blood, saliva, and tissue samples for research. The study also gathers information about your health behaviors and medical history.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Enrollment target
~250 participants
Started
January 2022
Primary completion
January 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Phu Lam
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.